Trial Profile
The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 Aug 2017
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C; Liver cancer
- Focus Therapeutic Use
- 04 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment as the supplies of study drug were halted by Gilead Sciences Ltd.
- 18 Nov 2016 New trial record